Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 107

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 107
---
 departures of key scientific or management personnel; |

| ● | unanticipated serious safety concerns related to the use of our product candidates; |

| ● | introduction of new drugs by our competitors; |

| ● | announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; |

| ● | any significant change in our management; |

| ● | our ability to effectively manage our growth; |

| ● | the size and growth of our initial target markets; |

| ● | actual or anticipated variations in quarterly operating results; |

| ● | our cash position; |

| ● | our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; |

| ● | the public’s response to press releases or other public announcements by us or third parties, including our filings with the SEC; |

| ● | publication of research reports about us or our industry, or microbiome therapies in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; |

| ● | guidance, if any, that we provide to the public, any changes in this guidance or our failure to meet this guidance; |

| ● | changes in the market valuations of similar companies; |

58

| ● | overall performance of the equity markets; |

| ● | sales of our Common Stock by us or our stockholders, in the future; |

| ● | trading volume of our Common Stock; |

| ● | investor perceptions of the investment opportunity associated with our Common Stock relative to other investment alternatives; |

| ● | actions by institutional or activist stockholders; |

| ● | change in accounting standards, policies, guidelines, interpretations or principles; |

| ● | ineffectiveness of our internal controls; |

| ● | disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; |

| ● | significant lawsuits, including patent or stockholder litigation; |

| ● | changes in the structure of healthcare payments systems; |

| ● | issuance of additional shares of our Common Stock to comply with the full ratchet antidilution rights contained in our outstanding Warrants; |

| ● | failure to raise additional funds on acceptable terms, or at all; |

| ● | changes in business or regulatory conditions, including new laws or regulations or new interpretations of existing laws or regulations applicable to our business; |

| ● | general political, economic, industry and market conditions, including rising interest rates and inflation; and